BioRestorative Therapies Announces CRO Agreement with PRC Clinical for its BRTX-100 Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease
December 21, 2021 16:01 ET
|
BioRestorative Therapies, Inc
MELVILLE, N.Y., Dec. 21, 2021 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company" or “BioRestorative”) (NASDAQ:BRTX), a life sciences company focused on adult stem cell-based...
BioRestorative Therapies CEO Interviewing Live on the James Hicks NewMedia Show
December 21, 2021 06:00 ET
|
BioRestorative Therapies, Inc
MELVILLE, N.Y., Dec. 21, 2021 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company" or “BioRestorative”) (NASDAQ:BRTX), a life sciences company focused on adult stem cell-based...
BioRestorative Therapies, Inc. Releases Year-End Message
December 20, 2021 06:00 ET
|
BioRestorative Therapies, Inc
MELVILLE, N.Y., Dec. 20, 2021 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company" or “BioRestorative”) (NASDAQ:BRTX), a life sciences company focused on adult stem cell-based...
BioRestorative Therapies Announces Filing of Ten Patent Applications Related to its BRTX-100 Program
December 02, 2021 06:00 ET
|
BioRestorative Therapies, Inc
MELVILLE, N.Y., Dec. 02, 2021 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company" or “BioRestorative”) (NASDAQ:BRTX), a life sciences company focused on adult stem cell-based...
BioRestorative Therapies Enters into Letter of Intent with PRC Clinical
November 19, 2021 06:00 ET
|
BioRestorative Therapies, Inc
PRC Clinical to Provide Start-up CRO Services for BRTX-100 Phase 2 Clinical Trial MELVILLE, N.Y., Nov. 19, 2021 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company" or...
BioRestorative Therapies Appoints Robert Kristal as Chief Financial Officer
November 10, 2021 06:00 ET
|
BioRestorative Therapies, Inc
MELVILLE, N.Y., Nov. 10, 2021 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company") (NASDAQ:BRTX), a life sciences company focused on adult stem cell-based therapies, today announced...
BioRestorative Therapies Announces Closing of $23 Million Public Offering
November 09, 2021 14:20 ET
|
BioRestorative Therapies, Inc
MELVILLE, N.Y., Nov. 09, 2021 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company") (NASDAQ:BRTX), a life sciences company focused on adult stem cell-based therapies, today announced...
BioRestorative Therapies Prices $23 Million Public Offering and Uplisting to the Nasdaq Capital Market
November 04, 2021 21:21 ET
|
BioRestorative Therapies, Inc
Common stock will begin trading on The Nasdaq Capital Market under the ticker symbol “BRTX” November 5, 2021 MELVILLE, N.Y., Nov. 04, 2021 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc....
BioRestorative Therapies Announces Implementation of Reverse Stock Split in Preparation for Planned Uplisting to Nasdaq
October 26, 2021 16:05 ET
|
BioRestorative Therapies, Inc
MELVILLE, NY, Oct. 26, 2021 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BRTX” or the “Company”) (OTC: BRTX), a life sciences company focused on adult stem cell-based therapies, today...
BioRestorative Therapies Announces Nomination of Two New Members to the Board of Directors
October 26, 2021 08:00 ET
|
BioRestorative Therapies, Inc
MELVILLE, N.Y., Oct. 26, 2021 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative” or the “Company”) (OTC: BRTX), a life sciences company focused on stem cell-based therapies, today...